Thanks, CGC! Great stuff, and 2 questions: 1. I

Thanks, CGC! Great stuff, and 2 questions:

1. I didn't see any reference to possible Alzheimers efficacy in your summary, likely because it's just a theoretical application at this point. But I have seen something called "Pepinemab" being developed to potentially treat Alzheimer’s, so -

Do you know if Leronlimab would have a similar MOA as Pepinemab? Or is Pepinemab better suited to tackle Alzheimer’s than Leronlimab?

2. Your write up mentioned 800 patients treated with Leronlimab - but isn't it over a 1,000? I thought I read where Dr J stated "over a thousand" in one of his talks.


Thanks again for your summary!